Employees: 11-50
Total raised: $15.5M
Founded date: 2017
Investors 2
| Date | Name | Website |
| - | Takeda Ven... | takeda.com |
| - | Arkin Hold... | arkinholdi... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 25.03.2020 | Series A | $15.5M | - |
Mentions in press and media 5
| Date | Title | Description |
| 25.03.2020 | Redpin Therapeutics Secures $15.5M in Series A | NEW YORK, NY, Redpin Therapeutics has secured $15.5 million in the initial closing of its Series A financing round led by 4BIO Capital. >> Click here for more funding data on Redpin Therapeutics >> To export Redpin Therapeut... |
| 25.03.2020 | Redpin Therapeutics Raises $15.5M In Series A | NEW YORK--(BUSINESS WIRE)--Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in ... |
| 25.03.2020 | 4BIO Capital leads Redpin Therapeutics’ $15.5 million Series A | LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company dev... |
| 25.03.2020 | Redpin Therapeutics Secures $15.5M in Initial Closing of Series A Financing | Redpin Therapeutics, Inc., a NYC-based chemogenetics company developing controllable gene therapies to address intractable diseases of the nervous system, secured $15.5m in the initial closing of its Series A financing round. The round was ... |
| 25.03.2020 | Redpin Therapeutics Raises $15.5M In Series A | NEW YORK--(BUSINESS WIRE)--Redpin Therapeutics, Inc., a pioneering chemogenetics company developing uniquely controllable gene therapies to address intractable diseases of the nervous system, today announced it has secured $15.5 million in ... |